Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Eileen M. Geoghegan"'
Autor:
Ravendra Garg, Kevin J. H. Allen, Wojciech Dawicki, Eileen M. Geoghegan, Dale L. Ludwig, Ekaterina Dadachova
Publikováno v:
Cancer Medicine, Vol 10, Iss 3, Pp 1128-1140 (2021)
ABSTRACT Purpose Despite the availability of new drugs, many patients with acute myeloid leukemia (AML) do not achieve remission and outcomes remain poor. Venetoclax is a promising new therapy approved for use in combination with a hypomethylating ag
Externí odkaz:
https://doaj.org/article/af252bdb1a414e8c8cac047a8543fb55
Autor:
Eileen M. Geoghegan, Diana V. Pastrana, Rachel M. Schowalter, Upasana Ray, Wei Gao, Mitchell Ho, Gary T. Pauly, Dina M. Sigano, Campbell Kaynor, Ellen Cahir-McFarland, Benoit Combaluzier, Jan Grimm, Christopher B. Buck
Publikováno v:
Cell Reports, Vol 21, Iss 5, Pp 1169-1179 (2017)
Summary: Progressive multifocal leukoencephalopathy (PML) is a lethal brain disease caused by uncontrolled replication of JC polyomavirus (JCV). JCV strains recovered from the brains of PML patients carry mutations that prevent the engagement of sial
Externí odkaz:
https://doaj.org/article/940b16d5a0d7411789fc82a19047a02f
Autor:
Mariano Prado Acosta, Eileen M. Geoghegan, Bernd Lepenies, Sandra Ruzal, Margaret Kielian, Maria Guadalupe Martinez
Publikováno v:
Frontiers in Microbiology, Vol 10 (2019)
Alphaviruses and flaviviruses are important human pathogens that include Chikungunya virus (CHIKV), Dengue virus (DENV), and Zika virus (ZIKV), which can cause diseases in humans ranging from arthralgia to hemorrhagic fevers and microcephaly. It was
Externí odkaz:
https://doaj.org/article/45c2f650fdbd43268a491dfe2f7d3bb0
Autor:
Dale Ludwig, Wojciech Dawicki, Ravendra Garg, Kevin J. H. Allen, Ekaterina Dadachova, Eileen M. Geoghegan
Publikováno v:
Cancer Medicine, Vol 10, Iss 3, Pp 1128-1140 (2021)
Cancer Medicine
Cancer Medicine
Purpose Despite the availability of new drugs, many patients with acute myeloid leukemia (AML) do not achieve remission and outcomes remain poor. Venetoclax is a promising new therapy approved for use in combination with a hypomethylating agent or wi
Autor:
Ravendra Garg, Eileen M. Geoghegan, Wojciech Dawicki, Mark S. Berger, Dale L. Ludwig, Kevin J. H. Allen, Ekaterina Dadachova
Publikováno v:
Oncotarget
Chimeric antigen receptor (CAR) T cell therapies, and adoptive cell therapy (ACT) in general, represent one of the most promising anti-cancer strategies. Conditioning has been shown to improve the immune homeostatic environment to enable successful A
Autor:
Ekaterina Dadachova, Kevin J. H. Allen, Wojciech Dawicki, Ravendra Garg, Eileen M. Geoghegan, Dale Ludwig
PurposeDespite the availability of new drugs, many patients with acute myeloid leukemia (AML) do not achieve remission and outcomes remain poor. Venetoclax is a promising new therapy approved for use in combination with a hypomethylating agent or wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::567b59194e3e6591c92506dfbbba42fc
https://doi.org/10.1101/2020.10.09.334151
https://doi.org/10.1101/2020.10.09.334151
Autor:
Mark B. Geyer, Eileen M. Geoghegan, Briana R. Cadzin, Dale L. Ludwig, Neeta Pandit-Taskar, Peter Kane, Brigitte Senechal, Mark S. Berger, Vijay Reddy, Craig S. Sauter, Elizabeth Halton
Publikováno v:
Blood. 138:4810-4810
Background: Autologous CD19-targeted chimeric antigen receptor-modified (CAR) T-cell therapy leads to complete responses (CR) in patients (pts) with (w/) relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL, >80% CR rate) and diffu
Autor:
Sagarika Pachhal, Jesse Hwang, Qing Liang, Denis Beckford, Helen Kotanides, Emily Greer, Eileen M. Geoghegan, Dale L. Ludwig, Mary Chen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundActimab-A, the anti-CD33 antibody lintuzumab armed with the radioisotope Actinium-225 (Ac-225), has demonstrated single agent antileukemic effects in patients with relapsed or refractory acute myeloid leukemia (AML). Up-regulation of CD47,
Autor:
Jesse Hwang, Mary Chen, Emily Greer, Qing Liang, Eileen M. Geoghegan, Dale L. Ludwig, Helen Kotanides, Sagarika Pachhal, Denis Beckford
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A619-A619
BackgroundOne mechanism that tumors use to escape immunosurveillance is the overexpression of CD47, which inhibits the macrophage mediated phagocytosis pathway. Although blockade of the CD47-SIRPα axis is a promising approach to enhance tumor target
Autor:
Wojciech Dawicki, Ravendra Garg, Kevin J. H. Allen, Qing Liang, Eileen M. Geoghegan, Dale L. Ludwig, Ekaterina Dadachova
Publikováno v:
Cancer Research. 81:1518-1518
Background: Bone marrow transplantation, ex vivo gene therapies targeting hematological disorders, and other forms of adoptive cell therapies (ACT) require complete or partial removal of the host immune cells by a process called conditioning. This is